Skip to main content

Table 1 Baseline characteristics of the overall study population and of patients grouped according to the receipt of ICIs within 30 days of death

From: PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

  Overall No ICIs administration within 30 days of death ICIs administration within 30 days of death  
N° (%) N° (%) N° (%)  
567 401 166  
Age     
 < 60 years old 148 (26.1) 111 (27.7) 37 (22.3) P = 0.1839
P = 0.9163
 ≥ 60 years old 419 (73.9) 290 (72.3) 129 (77.7)
 < 70 years old 323 (57.0) 229 (57.1) 94 (56.6)
 ≥ 70 years old 244 (43.0) 172 (42.9) 72 (43.4)
Gender     P = 0.1600
 Female 192 (33.9) 143 (37.5) 49 (29.5)
 Male 375 (66.1) 258 (64.3) 117 (70.5)
ECOG PS     P < 0.0001
 0—1 474 (83.6) 355 (88.5) 119 (71.7)
 ≥ 2 93 (16.4) 46 (11.5) 47 (28.3)
Primary tumor     P = 0.0707
 NSCLC 352 (62.1) 239 (59.6) 113 (68.2)
 Melanoma 111 (19.6) 89 (22.2) 22 (13.3)
 Renal cell carcinoma 83 (14.6) 60 (15.0) 23 (13.9)
 Others 21 (3.7) 13 (3.2) 8 (4.8)
No. of metastatic sites     P = 0.0266
 ≤ 2 214 (37.7) 163 (40.6) 51 (30.7)
 > 2 353 (62.3) 238 (59.4) 115 (69.3)
Type of anti-PD-1/PD-L1 agent     P = 0.5445
 Pembrolizumab 168 (29.6) 123 (30.7) 45 (27.1)
 Nivolumab 370 (65.3) 258 (64.3) 112 (67.5)
 Atezolizumab 18 (3.2) 11 (2.7) 7 (4.2)
 Others 11 (1.9) 9 (2.2) 2 (1.2)
Treatment line     P = 0.8895
 First 173 (30.5) 123 (30.7) 50 (28.9)
 Second 324 (57.1) 227 (56.6) 97 (58.4)
 Further lines 70 (12.3) 51 (12.7) 19 (11.4)
Best responsea     P = 0.4693
 PR/CR 403 (79.5) 300 (78.7) 103 (81.7)
 PD/SD 104 (20.5) 81 (21.3) 23 (18.3)
Time to treatment failure     P = 0.0028
 ≥ 3 months 308 (54.3) 234 (58.4) 74 (44.6)
 < 3 months 259 (45.7) 167 (41.6) 92 (55.4)
  1. a507 evaluable patients for best response. ICI: immune checkpoint inhibitor; ECOG-PS: eastern cooperative oncology group performance status; NSCLC: non-small cell lung cancer; PD-1/PD-L1: programmed death-1/programmed death-ligand 1; PR: partial response; CR: complete response; PD: progressive disease; SD: stable disease